by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
by Mark Curtis | Jan 7, 2014
. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with...
by Paul Krzyzanowski | Dec 16, 2013
> This is part three of an interview series with Michael West, CEO of BioTime. Read parts one and two. The prospects for BioTime and other companies that operate in the tissue engineering and cell therapy market are good. The industry is growing by about 18% per...
by Mark Curtis | Nov 27, 2013
. Welcome to the regenerative medicine deal review for the month of November. Cytori Therapeutics and Lorem Vascular have teamed up to catalyze the commercialization of Cytori cell therapies using its proprietary Celution® System in Asia. There was also a notable deal...
by Mark Curtis | Nov 19, 2013
. Welcome to October’s Update from the Clinic. Interesting developments this past month included the release of Phase 1/2a data from Living Cell Technologies that provides a first look at the safety and efficacy of its DIABECELL® product. We also saw an approval for...
by Stacey Johnson | Nov 15, 2013
. Sometimes too much choice can be a bad thing. It paralyzes you. I was flummoxed by the many options available to me in selecting what to feature on Right Turn this week. Then it struck me: I have the perfect item right under my nose (so to speak). CCRM just launched...
Comments